NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 161)
Posted On: 07/17/2023 4:22:00 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver the NPRL2 tumor suppressor gene ‘positions Genprex to expand our clinical pipeline with a new drug candidate’ and gives the company ‘further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.’”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver the NPRL2 tumor suppressor gene ‘positions Genprex to expand our clinical pipeline with a new drug candidate’ and gives the company ‘further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.’”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼